@RSV2022

#RSV2022 symposium in @BelfastICC for ISIRV. Lots of chat about #RSV #VRS #RSVAwareness @VisitBelfast @BelfastTourism

[@RSV2022 @rsv2022]

A huge thank you to our organising committee @UltanPower @NATBASH15 @sbdrysdale @LindsayBbent

Also a huge thank you to Rita from ISIRV and the international RSV committee.

We have had an amazing conference! #RSV2022

[Ralph A. Tripp @ratripp]

Nirsevimab and Hospitalization for RSV Bronchiolitis | New England Journal of Medicine https://t.co/IcJPD0skGR

[Ralph A. Tripp @ratripp]

Epidemiology of RSV in Adults and Children with Medically-Attended Acute Respiratory Illness over Three Seasons https://t.co/ZwORhQmE7P

[Charlotte Vernhes @CCVernhes]

A 2023 paper published in @JIDJournal by the @RESCEUproject characterising the #RSV associated hospitalisations in children under 5 in EU countries and Norway @IHIEurope

[Ultan Power @UltanPower]

At last, we got the opportunity to present the @rsv2022 Jose Antonio Melero Early Career Investigator award to Dr. Vahid Salimi at #RSVVW23. Congrats again Vahid! Thanks to @p_openshaw for doing the honours!
https://t.co/UBzyDNnOJ5

[John Paget, PhD @PagetPhd]

Rapidly increasing weekly RSV detections in Lyon, France (see orange line)

▶️ Large majority RSV A
▶️ Highest positivity rates (60%): <1 years
▶️ Low positivity rates (<3%) in the elderly (65+ years)
▶️ Influenza detections are low (red line)

[National Coalition for Infant Health @InfantCoalition]

Last week @InfantCoalition was pleased to have a poster @RSV2022 symposium in Belfast, Northern Ireland to share info on shaping RSV access & prevention policies with the intl #RSV community. #RSVAwareness #RSV2022

Learn more about RSV: https://t.co/XDqnM5CxJ6

[Pablo Murcia (he/him) @PabloRMurcia]

Thanks to the organisers of @RSV2022 . The breadth of topics and the quality of the talks were inspiring.

[@RSV2022 @rsv2022]

@jo__haney @PabloRMurcia @SwethaVijayakr1 @SCMICryoEM @CVRinfo So glad you enjoyed the conference! The quality of science was fantastic. RSV2024 will have a lot to live up to 😄

[@RSV2022 @rsv2022]

@LucyMosscrop @mvcbarnes @_amber_owen So glad you had a great time! Hopefully we will see you again in 2 years 😁

[Lucy Mosscrop @LucyMosscrop]

Had a fantastic few days in Belfast at my first RSV conference @rsv2022. The standard of talks and posters was extremely high and I’ve left with lots of ideas! Congratulations to fellow imperial PhD students @mvcbarnes @_amber_owen who both gave fantastic talks 🤩

[Jo Haney @jo__haney]

Had a brilliant time taking in all the great science at @RSV2022, thank you to the organisers for having me! Really enjoyed sharing our work on RSV-flu hybrid virions, paper to follow soon!🔬 @PabloRMurcia @SwethaVijayakr1 @SCMICryoEM @CVRinfo

[@RSV2022 @rsv2022]

We have had fantastic representation among speakers and delegates, over 30 countries represented by attendees!
@UltanPower

[NATASHA HALASA @NATBASH15]

Proud of the diverse speakers - scoring of oral presentations were blinded - majority of oral abstract winners were women! Also - the Chair of @rsv2022 Dr. Ultan Power was deliberate to make sure keynote speakers had gender and geographic balance.

https://t.co/xLn1lWKN67

[@RSV2022 @rsv2022]

@JimBoonyaratana @mvcbarnes @EstefanyRiosGuz

[@RSV2022 @rsv2022]

Congratulations to all of our prize winners! 🏆

1st place oral: Jim Boonyaratanaknornkit
2nd place oral: Kevin Groen
Best ECR oral: Megan Barnes

Best Poster: Elisabeth Robinson
Poster runner ups: Quinten Kieser, Sarah Hak, Estefany Rios Guzman

[Simon Drysdale @sbdrysdale]

The BIG debate to close @rsv2022 ….bring it on!

[@RSV2022 @rsv2022]

Our last keynote of #RSV2022 is Prof Adnan Custovic from @imperialcollege on Machine Learning in Asthma

[Simon Drysdale @sbdrysdale]

Excellent talk on BronchStart #RSV study by @Williams_T_C @rsv2022

[@RSV2022 @rsv2022]

We have two keynote talks during our Big Data and RSV session. The first is Prof Cheryl Cohen on how we can use data to guide policy.

[Thomas Christie Williams @Williams_T_C]

now @rsv2022 Prof. Cheryl Cohen @WitsUniversity talks about key considerations in implementing an RSV vaccine 1/n